Skip to content
BioAI Health logo — Revolutionizing precision medicine with the power of predict...

BioAI Health

Revolutionizing precision medicine with the power of predictive biomarkers.

Founded 2020 United States Manchester, United States 18 employees Seed Total: $3.50M Biotechnology, Health Care

General Information

Company Name BioAI Health
Founded Year 2020
Location United States Manchester, United States
Employees 18
Industries Biotechnology, Health Care
Funding Stage Seed
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Usage Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with BioAI Health. To contact BioAI Health, visit bioaihealth.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioAI Health compare?

A PDF of BioAI Health and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioAI Health soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioAI Health

BioAI, founded in 2020, is at the cutting edge of integrating multimodal AI to advance precision medicine. Headquartered in the United States, the company’s slogan, "Transforming Precision Medicine with Multimodal AI," captures its core mission of leveraging machine learning to unravel the causal biology of diseases, develop digital biomarkers, and identify novel drug targets.

The company’s flagship product, the PredictX Platform, offers a sophisticated toolset for analyzing a variety of data sources including Digital Pathology, Multiomics, and Real-World Evidence. This platform helps construct predictive and prognostic models across numerous therapeutic areas by deploying advanced methodologies such as in-silico phenotype projection and integrated deep learning.

With a strong track record of forming strategic partnerships within the Pharma industry, BioAI continues to deliver innovative solutions to its global clientele. The company’s recent financial milestone was a $500.00K Seed Round investment on 05 April 2024, underscoring investor confidence in its technological and business propositions.

Business keywords: Precision Medicine, Multimodal AI, Digital Biomarkers, Drug Target Identification, Digital Pathology, Multiomics, Real-World Evidence, In-silico Phenotype Projection, Deep Learning, Biotech, Translational Studies, Clinical Trials, Predictive Modeling, Therapeutic Areas

Services & Products

Advanced tests and biomarker panels development
AI models for genetic mutations screening
Clinical diagnostics via PredictLung
Data and biospecimen sourcing services
Precision diagnostic assays development

Target Customers

Clinicians Biopharma companies Clinical researchers Hospitals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $500.00K -
05 Apr 2024
Seed Round $3.00M 1
Biomedical Investments
20 Sep 2022

BioAI Health Alternatives & Competitors

View All Alternatives
BioAI Health vs
PathAI
PathAI United States

Improving patient outcomes with AI-powered pathology.

Debt Financing
277 employees
Biotechnology, Health Care
BioAI Health vs

Pioneering AI-based cancer diagnostics in pathology

Series C
95 employees
AI, Analytics
BioAI Health vs

Radiomics, Deep Learning & Federated Learning for AI powered drug development trajectory and persona...

24 employees
AI, Biotechnology

FAQ About BioAI Health

Revolutionizing precision medicine with the power of predictive biomarkers.
BioAI Health was founded in 2020.
BioAI Health is headquartered in Manchester, United States.
BioAI Health operates in Biotechnology and Health Care. Its work centres on Precision Medicine, Multimodal AI, Digital Biomarkers and Drug Target Identification. Its customers include Clinicians, Biopharma companies and Clinical researchers.
BioAI Health has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Usage Based and Service Fee.
BioAI Health has approximately 18 employees.
BioAI Health has completed 2 funding rounds, raising a total of $3.50M. The latest funding stage is Seed.
BioAI Health offers: Advanced tests and biomarker panels development, AI models for genetic mutations screening, Clinical diagnostics via PredictLung, Data and biospecimen sourcing services, Precision diagnostic assays development.
Top alternatives and competitors to BioAI Health include PathAI, Ibex Medical Analytics, radiomics.bio, Nova In Silico, xCures. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioAI Health and PathAI are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioAI Health, https://www.bouncewatch.com/company/bioai, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout